A Study to Evaluate the Pharmacokinetics and Bioequivalence of Sumatriptan Delivered Via the Intraject System

Inclusion Criteria: * Healthy subjects * Negative serum pregnancy test * Female subjects of child-bearing potential must agree to use acceptable birth control 3 weeks prior to and 2 weeks after study dosing. * Body Mass Index (BMI) and sufficient subcutaneous thickness, in the opinion of the investigator, for an injection into the abdomen, arm and thigh * Non-tobacco user * Adequate venous access in the left or right arm to allow collection of a number of blood samples * Fluent in the English language * Provide written informed consent to participate in the study and be willing to comply with the study procedures Exclusion Criteria: * History within the previous 2 years of drug or alcohol dependence * Evidence of clinically relevant oral, cardiovascular, hematologic, gastrointestinal, hepatic, renal, endocrine, pulmonary, neurologic, psychiatric or skin disorder * History of epilepsy or other neurologic disease * History of coronary disease, peripheral vascular disease, cerebrovascular accident, transient ischemic attack, uncontrolled hypertension, or signs/symptoms of ischemic heart disease * History of allergy, anaphylaxis, or hypersensitivity to sumatriptan or similar drugs including sulphonamides * History of scleroderma or any skin condition that may adversely affect the injection or absorption of subcutaneously administered medications * Tattoos or birthmarks in the lateral thigh, abdominal area or arm (deltoid) that are large enough to restrict injection site selection and/or evaluation * Positive screening test for HIV antibodies, Hepatitis B surface antigen, or Hepatitis C antibody * Positive results on illicit drug test at Screening or at Check-in * Use of any prescription medication